Total Payments
$6,301
2024 Payments
$5,204
Companies
10
Transactions
27
Medicare Patients
5,008
Medicare Billing
$2.4M
Payment Breakdown by Category
Consulting$5,030 (79.8%)
Food & Beverage$1,271 (20.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,030 | 3 | 79.8% |
| Food and Beverage | $1,271 | 24 | 20.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $4,230 | 2 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $870.26 | 4 | $0 (2024) |
| Genentech USA, Inc. | $531.04 | 9 | $0 (2024) |
| Genentech, Inc. | $214.12 | 2 | $0 (2023) |
| Sight Sciences, Inc. | $142.00 | 1 | $0 (2022) |
| Alcon Vision LLC | $128.45 | 2 | $0 (2024) |
| Allergan, Inc. | $76.75 | 2 | $0 (2021) |
| Apellis Pharmaceuticals, Inc. | $53.99 | 2 | $0 (2023) |
| Horizon Therapeutics plc | $42.80 | 2 | $0 (2020) |
| Johnson & Johnson Surgical Vision, Inc. | $12.07 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,204 | 8 | Regeneron Pharmaceuticals, Inc. ($4,230) |
| 2023 | $461.07 | 8 | Genentech USA, Inc. ($291.61) |
| 2022 | $378.90 | 4 | Sight Sciences, Inc. ($142.00) |
| 2021 | $110.40 | 4 | Allergan, Inc. ($76.75) |
| 2020 | $42.80 | 2 | Horizon Therapeutics plc ($42.80) |
| 2019 | $104.63 | 1 | Alcon Vision LLC ($104.63) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $32.43 | General |
| Category: Ophthalmology | ||||||
| 10/10/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: Ophthalmology | ||||||
| 09/26/2024 | Alcon Vision LLC | Clareon (Device) | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: Ophthalmology | ||||||
| 09/19/2024 | Bausch & Lomb Americas Inc. | STELLARIS ELITE (Device) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: Ophthalmology | ||||||
| 05/21/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $62.60 | General |
| Category: Immunology and Ophthalmology | ||||||
| 02/28/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $33.38 | General |
| Category: Immunology and Ophthalmology | ||||||
| 01/26/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,350.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 01/26/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $1,880.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/20/2023 | Genentech, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $115.47 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/12/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $28.71 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/04/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $29.46 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/31/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $122.06 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/05/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $86.20 | General |
| Category: Immunology and Ophthalmology | ||||||
| 05/09/2023 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $37.03 | General |
| 04/26/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $16.96 | General |
| Category: Ophthalmology | ||||||
| 03/06/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/25/2022 | Genentech, Inc. | Lucentis (Biological), SUSVIMO, VABYSMO | Food and Beverage | In-kind items and services | $98.65 | General |
| Category: Ophthalmology | ||||||
| 06/01/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $121.87 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/06/2022 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: Ophthalmology | ||||||
| 02/16/2022 | Sight Sciences, Inc. | OMNI(R) SURGICAL SYSTEM (US) (Device) | Food and Beverage | In-kind items and services | $142.00 | General |
| Category: Ophthalmology | ||||||
| 11/11/2021 | Allergan, Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: RETINA | ||||||
| 06/24/2021 | Johnson & Johnson Surgical Vision, Inc. | Tecnis Simplicity (Device), Tecnis IOL, CATALYS SYSTEM | Food and Beverage | In-kind items and services | $12.07 | General |
| Category: Optics | ||||||
| 06/03/2021 | Allergan, Inc. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $54.83 | General |
| Category: GLAUCOMA | ||||||
| 04/19/2021 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $21.58 | General |
| 02/19/2020 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: TEPEZZA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 2,216 | 11,459 | $3.9M | $1.8M |
| 2022 | 14 | 1,042 | 1,460 | $693,736 | $267,121 |
| 2021 | 16 | 1,033 | 1,333 | $653,354 | $175,249 |
| 2020 | 11 | 717 | 920 | $394,577 | $119,415 |
Total Patients
5,008
Total Services
15,172
Medicare Billing
$2.4M
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 248 | 2,019 | $2.4M | $1.4M | 57.5% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 30 | 5,460 | $273,000 | $158,572 | 58.1% |
| 67028 | Injection of drug into eye | Office | 2023 | 350 | 1,211 | $782,650 | $106,771 | 13.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 400 | 784 | $94,080 | $49,237 | 52.3% |
| 92134 | Imaging of retina | Office | 2023 | 589 | 1,228 | $122,800 | $35,014 | 28.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 227 | 227 | $56,750 | $27,430 | 48.3% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 13 | 13 | $27,300 | $11,429 | 41.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 104 | 112 | $19,600 | $10,878 | 55.5% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 78 | 145 | $39,780 | $9,740 | 24.5% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 65 | 132 | $34,320 | $7,393 | 21.5% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2023 | 14 | 17 | $27,200 | $4,368 | 16.1% |
| 92250 | Photography of the retina | Office | 2023 | 47 | 51 | $5,520 | $1,360 | 24.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 11 | 11 | $2,420 | $1,105 | 45.7% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 20 | 27 | $4,660 | $959.66 | 20.6% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 20 | 22 | $1,210 | $422.44 | 34.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 70 | 238 | $288,066 | $168,617 | 58.5% |
| 67028 | Injection of drug into eye | Office | 2022 | 179 | 296 | $198,600 | $28,562 | 14.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 143 | 143 | $35,750 | $18,353 | 51.3% |
| 92134 | Imaging of retina | Office | 2022 | 274 | 333 | $34,560 | $10,312 | 29.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 130 | 144 | $17,320 | $10,082 | 58.2% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2022 | 31 | 31 | $20,100 | $5,400 | 26.9% |
| 67113 | Complex repair of detached retina and drainage of eye fluid between lens and retina | Facility | 2022 | 30 | 31 | $23,250 | $5,297 | 22.8% |
| J7999 | Compounded drug, not otherwise classified | Office | 2022 | 42 | 67 | $17,980 | $4,469 | 24.9% |
| 99284 | Emergency department visit for problem of high severity | Facility | 2022 | 43 | 43 | $9,675 | $3,964 | 41.0% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2022 | 22 | 22 | $15,400 | $3,570 | 23.2% |
About Samir Patel
Samir Patel is a Ophthalmology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/01/2016. The National Provider Identifier (NPI) number assigned to this provider is 1568825057.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Samir Patel has received a total of $6,301 in payments from pharmaceutical and medical device companies, with $5,204 received in 2024. These payments were reported across 27 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($5,030).
As a Medicare-enrolled provider, Patel has provided services to 5,008 Medicare beneficiaries, totaling 15,172 services with total Medicare billing of $2.4M. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Philadelphia, PA
- Active Since 04/01/2016
- Last Updated 07/09/2020
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1568825057
Products in Payments
- EYLEA HD (Biological) $4,230
- STELLARIS ELITE (Device) $800.00
- Vabysmo (Drug) $503.06
- OMNI(R) SURGICAL SYSTEM (US) (Device) $142.00
- VABYSMO (Drug) $121.87
- Lucentis (Biological) $98.65
- Stellaris (Device) $70.26
- DURYSTA (Drug) $54.83
- TEPEZZA (Drug) $42.80
- Clareon (Device) $23.82
- OZURDEX (Drug) $21.92
- Syfovre (Drug) $16.96
- Tecnis Simplicity (Device) $12.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Philadelphia
Robert Sergott, Md, MD
Ophthalmology — Payments: $1.7M
Ophthalmology $1.7M
Mark Blecher, Md, MD
Ophthalmology — Payments: $591,672
Ophthalmology $591,672
Dr. Joshua Greene, Md, MD
Ophthalmology — Payments: $488,392
Ophthalmology $488,392
Joseph Markoff, Md Phd, MD PHD
Ophthalmology — Payments: $441,634
Ophthalmology $441,634
Dr. Jonathan Myers, M.d, M.D
Ophthalmology — Payments: $412,982
Ophthalmology $412,982
Beeran Meghpara, M.d, M.D
Ophthalmology — Payments: $330,295
Ophthalmology $330,295